About SCI-ENGI-MEDCO SOLUTIONS, INC
SEMCO develops AAAPT technology to target cancer cells while protecting normal cells, reducing side effects and improving the efficacy of cancer treatments. The technology activates apoptosis pathways in tumor cells to enhance chemotherapy and other therapies.
A Priori Activation of Apoptosis Pathways of Tumor (AAAPT) technologyReduction of chemotherapy side effectsSensitization of cancer cells to treatmentsCombination therapy potential with chemotherapy, immunotherapy, and targeted therapyPotential for long-term remission
Is this your company?
Claim this profile to keep it accurate — and see the federal & state opportunities GovIntel's AI has matched to SCI-ENGI-MEDCO SOLUTIONS, INC right now.
Claim this profile See matched opportunitiesData compiled from public government sources including SAM.gov, USAspending.gov, and state procurement records. Last verified against federal award records. Inaccurate? Let us know.